1. Zips DP, Libby P, Bonow R, Braunwald E.
Braunwald’s heart disease: A textbook of
cardiovascular medicine. 7th ed. Philadelphia:
W.B. Saunders, 2015:963-1007, 419-21. 2. Flynn JT. Hypertension in the young:
epidemiology, sequelae and therapy. Nephrol
Dial Transplant 2009 Feb;24(2):370-5. 3. Moore WE, Stephens A, Wilson T, Wilson W,
Eichner JE. Peer reviewed: body mass index
and blood pressure screening in a rural public
school system: the Healthy Kids Project. Prev
Chronic Dis. 2006 Oct;3(4):A114. 4. Sorof JM, Lai D, Turner J, Poffenbarger T,
Portman RJ. Overweight, ethnicity, and the
prevalence of hypertension in school-aged
children. Pediatrics 2004 Mar;113(3 Pt 1):475-
82. 5. Dustan HP, Schneckloth RE, Corcoran AC. The
effectiveness of long term treatment of
malignant hypertension. Circulation 1958 Oct;
18(4 Part 1):644-51. 6. Beck JD, Offenbacher S. Systemic effects of periodontitis: epidemiology of periodontal
disease and cardiovascular disease. J
Periodontol 2005 Nov;76(11 Suppl):2089-100. 7. Vaughan CJ, Delanty N. Hypertensive
emergencies. Lancet 2000;356:411-17. 8. Topel LA, Kragelund C, Reibel J, Nauntofte B.
Oral adverse drug reactions to cardiovascular
drugs. Crit Rev Oral Biol Med 2004 Jan; 15(1):
28-46. 9. Arunkumar SH, Kalappanavar AN, Annigeri
RG, Shakunthala GK. Adverse oral
manifestations of cardiovascular drugs. J Dent
Med Sci 2013 Jun;7(5);64-71. 10. Bakhtiari S, Sehatpour M, Mortazavi H,
Bakhshi M. Orofacial manifestations of adverse
drug reactions: a review study. Clujul Med 2018
Jan;91(1):27-36. 11. Yuan A, Woo SB. Adverse drug events in the
oral cavity. Oral Surg Oral Med Oral Pathol Oral
Radiol 2015 Jan;119(1):35-47. 12. Femiano F, Lanza A, Buonaiuto C, Gombos F,
Rullo R, Festa V, et al. Oral manifestations of
adverse drug reactions: guidelines. J Eur Acad
Dermatol Venereol 2008 Oct;22:681-91. 13. Pamlona MC, Soriano YJ, Perez MGS. Dental
considerations in patients with heart disease. J
clin Exp Dent 2011 Dec;3(2):e97-105. 14. Glick M, Feagans WM. Burket’s oral
medicine. Shelton. 2015. 12th ed. Chap 4-6,10. 15. Sultana N, Sham EM. Xerostomia an
overview. Int J Clin Dent. 2011 Apr;3(2):58-61. 16. Zavras AI, Rosenberg GE, Danielson JD,
Cartsos VM. Adverse drug and device reactions
in the oral cavity: surveillance and
reporting. J Am Dent Assoc 2013 Sep; 144(9):
1014-21. 17. Edwards D, Boritz E, Cowen EW, Brown RS.
Erythema multiforme major following
treatment with infliximab. Oral Surg Oral Med
Oral Pathol Oral Radiol 2013 Feb;115(2):e36-
e40. 18. Jayakaran TG. The effect of drugs in the oral
cavity - A review. J Pharm Sci Res 2014 Feb; 6
(2):89-96. 19. Habbab KM, Moles DR, Porter SR. Potential
oral manifestations of cardiovascular drugs.
Oral Dis 2010 Nov;16(8):769-73. 20. Kumar P, Mastan KM, Chowdhary R,
Shanmugam K. Oral manifestations in
hypertensive patients: A clinical study. J Oral
Maxillofac Pathol 2012 May-Aug;16(2):215–
221. 21. Villa A, Abati S. Risk factors and symptoms
associated with xerostomia: a cross-sectional
study. Aust Dent J 2011 Sep;56(3):290-5. 22. Valizadeh GH-A, Bijani M, Bahramali E,
Kouhpayeh A. Investigating the consistency rate
of hypertension treatment through guide line
JNC-7, in patients who were referred to health
centers and health houses of Fasa University of
Medical Sciences 2012. J Fasa Univ Med Sci
2014 Jun;4(1):74-80. 23. William J, Elliott MD. Drug interactions and
drugs that affect blood pressure. J Clin
Hypertens 2006 Oct;8(10):731-7. 24. Wright JM. Choosing a first – line drug in the
management of elevated blood pressure: what
is the evidence? CMAJ 2000 Jul;163(1):57-60. 25. Shirzaiy M, Bagheri F. Prevalence of
xerostomia and its related factors in patients
referred to Zahedan Dental School in Iran. DCEJ
2016 Feb;2(1):e7138. 26. Little JW, Falace DA, Miller CS, Rhodus NL.
Drug and alcohol abuse: Dental management of
the medically compromised patient. 8th ed. St
Louis: Mosby Elsevier; 2018; 33-44: 562-75.
|